AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2
slide-3

Sitaglize-M 50/500 Tablet

Prescription Icon
Prescription Required

Marketer

Chemo Healthcare Pvt Ltd

Salt Composition

Sitagliptin (50mg) + Metformin (500mg)

Overview Sitaglize-M 50/500 Tablet

Combiflex-DM 50/500 tablets combine two medications to manage elevated blood glucose in type 2 diabetes patients. This dual action helps prevent serious diabetic complications like vision loss and kidney impairment, potentially lowering heart attack and stroke risks. Combiflex-DM 50/500 may be used alone or with other antidiabetic drugs, and is most effective with a balanced diet and regular physical activity. Dosage is personalized based on your health status, blood sugar readings, and other medications. Consuming it with meals minimizes stomach upset. Consistent daily dosing at the same time maximizes benefits; discontinue only under your physician's guidance. Adherence to your doctor's dietary and exercise plan is crucial for diabetes control, as lifestyle significantly impacts blood sugar management. Common side effects include nausea, diarrhea, vomiting, stomach discomfort, headache, and throat irritation. Low blood sugar (hypoglycemia) is a potential adverse effect when used concurrently with insulin or sulfonylureas; learn to recognize and treat this condition. This medication isn't for everyone. Inform your doctor of any pre-existing kidney, liver, or heart conditions, pancreatic issues, or significant alcohol consumption before starting treatment. Pregnant or lactating individuals require medical consultation. Potential drug interactions exist; disclose all medications to your doctor. Alcohol should be avoided due to its hypoglycemic effects. Your doctor will monitor kidney function and blood glucose levels throughout your treatment.

Uses of Sitaglize-M 50/500 Tablet

Managing type 2 diabetes

Major Benefits of Sitaglize-M 50/500 Tablet:

Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Sitaglize-M 50/500 Tablet whole; do not crush, chew, or break it. Administer this medication with food.

Common Side effects of Sitaglize-M 50/500 Tablet:

  • Decreased appetite
  • Vomiting
  • Upper respiratory tract infection
  • Hypoglycemia (low blood glucose level)
  • Abdominal bloating
  • Nausea
  • Diarrhea

How to use Sitaglize-M 50/500 Tablet:

Consume this medication precisely as your physician directs, adhering to the prescribed dosage and timeframe. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. It's recommended to take Sitaglize-M 50/500 Tablet with a meal.

How Sitaglize-M 50/500 Tablet works:

Sitagliptin and metformin, combined as Sitaglize-M 50/500 tablets, work synergistically to manage blood glucose. Sitagliptin enhances insulin production by the pancreas, improves insulin utilization, and decreases hepatic glucose output. Metformin, a biguanide, reduces liver glucose production, slows intestinal glucose absorption, and enhances insulin sensitivity. This dual action leads to superior blood sugar regulation.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Sitaglize-M 50/500 Tablet with alcohol is not advisable due to safety concerns.

PregnancyPregnancyCONSULT YOUR DOCTOR

The use of Sitaglize-M 50/500 Tablet during pregnancy may pose risks. While human research is scant, animal studies indicate potential harm to the fetus. A physician will assess the advantages against possible risks prior to prescription. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

The use of Sitaglize-M 50/500 tablets while breastfeeding is likely inadvisable. Available human data indicates potential transfer of the medication into breast milk, posing a possible risk to the infant.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these blood sugar imbalances.

KidneyKidneyCAUTION

Patients with kidney impairment should use Sitaglize-M 50/500 Tablets cautiously, potentially requiring dosage modification. Severe kidney disease contraindicates the use of Sitaglize-M 50/500 Tablets. Physician consultation is essential. Regular monitoring of kidney function is recommended during treatment.

LiverLiverUNSAFE

Individuals with hepatic impairment should likely refrain from using Sitaglize-M 50/500 tablets due to potential safety concerns. Medical advice is recommended.

What if you forget to take Sitaglize-M 50/500 Tablet :

Should you forget a Sitaglize-M 50/500 Tablet dose, administer it at your earliest convenience. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Sitaglize-M 50/500 Tablet

LabelValue
Developing Habits No.
Treatment Category Diabetes Medication

FAQs on Sitaglize-M 50/500 Tablet

Sitaglize-M 50/500 tablets combine sitagliptin and metformin to treat type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Prolonged Sitaglize-M 50/500 Tablet use can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, and balance problems), and urinary issues, potentially impacting mental function. To mitigate these risks, annual supplemental vitamin B12 is recommended by some researchers.
Sitaglize-M 50/500 Tablet may cause common side effects including hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects such as lactic acidosis can occur. Prolonged use may result in vitamin B12 deficiency.
Patients with known allergies to Sitaglize-M 50/500 Tablet components or excipients, or those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis should not use this medication.
Combining Sitaglize-M 50/500 tablets with alcohol is unsafe and may raise your risk of lactic acidosis.
Store this medication in its original, tightly closed container as directed on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Sitagliptin/Metformin (Sitaglize-M 50/500) can cause lactic acidosis, a serious medical emergency characterized by excessive blood lactic acid (also known as Metformin-Associated Lactic Acidosis or MALA). This rare side effect necessitates caution in patients with kidney disease, the elderly, or those who consume significant alcohol. Symptoms include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If these occur, discontinue Sitagliptin/Metformin and seek immediate medical attention.
Sitaglize-M 50/500 Tablet combines sitagliptin and metformin to treat type 2 diabetes in adults. It helps control blood sugar when used with diet and exercise. Metformin reduces liver glucose production and improves insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. This combination is not suitable for individuals under 18.
Sitaglize-M 50/500 Tablet may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Sitaglize-M 50/500 Tablets are contraindicated in patients with hypersensitivity to any ingredient. Avoid use in patients with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Sitaglize-M 50/500 tablets with alcohol is unsafe and may heighten the risk of lactic acidosis.
Sitagliptin/Metformin (Sitaglize-M 50/500) can cause lactic acidosis, a serious, potentially fatal condition resulting from excessive blood lactic acid (also known as Metformin-associated lactic acidosis, or MALA). This rare side effect necessitates caution in patients with kidney disease, older adults, and heavy alcohol users. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If these occur, discontinue Sitagliptin/Metformin and seek immediate medical attention.
Prolonged Sitaglize-M 50/500 Tablet use can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, urinary issues, cognitive changes, and ataxia), if left unaddressed. To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Store this medication in its original, tightly closed container, as directed on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Sitaglize-M 50/500 tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin boosts insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Sitaglize-M 50/500 Tablet may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Patients with known allergies to Sitaglize-M 50/500 Tablet components or excipients, or with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis should not use this medication.
Combining Sitaglize-M 50/500 tablets with alcohol is unsafe and may heighten the risk of lactic acidosis.
Sitagliptin/Metformin (Sitaglize-M 50/500 Tablet) can cause lactic acidosis (MALA – Metformin-associated lactic acidosis), a serious medical emergency resulting from excessive blood lactic acid. This rare side effect necessitates avoiding this medication in individuals with kidney disease, the elderly, or those who consume large quantities of alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If experienced, discontinue Sitagliptin/Metformin immediately and seek medical attention.
Prolonged Sitaglize-M 50/500 Tablet use can lead to vitamin B12 deficiency by impairing its absorption. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, and urinary issues), and cognitive changes (including balance problems). To mitigate these risks, supplemental vitamin B12 is recommended annually by some researchers.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication safely and ensure it remains inaccessible to children, pets, and others.
Sitaglize-M 50/500 Tablet
181
MRP 210
13% off